Advances in the management of craniopharyngioma in children and adults
, , , , , , oraz
25 paź 2019
O artykule
Kategoria artykułu: Review
Data publikacji: 25 paź 2019
Zakres stron: 388 - 396
Otrzymano: 21 cze 2019
Przyjęty: 11 lip 2019
DOI: https://doi.org/10.2478/raon-2019-0036
Słowa kluczowe
© 2019 Mojca Jensterle, Soncka Jazbinsek, Roman Bosnjak, Mara Popovic, Lorna Zadravec Zaletel, Tina Vipotnik Vesnaver, Barbara Faganel Kotnik, Primoz Kotnik, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1

Comparison of pediatric and adult-onset craniopharyngioma characteristics
Pediatric-onset | Adult-onset | |
---|---|---|
30–50 % of all CPs | ||
Age at presentation | Peak at 5–14 years1 | Peak at 40–44 years2 |
Gender distribution (m/f) | Equal8,21 | Equal8,27 |
Most frequent presentation | Headache (68–85%) | Visual impairment (40–84%) |
Visual impairment (36– 55%) | Menstrual irregularities (57%) | |
Growth failure (7–36%)9,35,66 | Headache (42–56%)13,26,27 | |
Pathohistological type | Adamantinomatous 99% | 33 |
Papillary extremely rare* | Papillary 14–50% | |
Initial hypothalamic involvement | 42–66%8,9,35 | 42%18 |
Endocrine deficits at diagnosis | ||
Any | 40–87%8,13,21,35,65,66 | 41–73%8 |
GH | 41–75%8,13,21,35,65,66 | 18–86%8,13 |
FSH/LH | 20–56%8,13,21,35,65,66 | 29–74%8,13 |
ACTH | 8–68%8,13,21,35,65,66 | 35–58%8,13 |
TSH | 15–32%8,13,21,35,65,66 | 35–56%8,13 |
ADH | 7–17%8,13,21,35,65,66 | 6–17%8,13 |
Pituitary hormone deficiencies after treatment | ||
Any | 64–100%8,64 | 48–97%8,64 |
GH | 93–96%8,18,21 | 52–68%8,18 |
FSH/LH | 59–95%8,18,21 | 70–94%8,18 |
ACTH | 78–100%8,18,21 | 74–88%8,18 |
TSH | 86–100%8,18,21 | 81–92%8,18 |
ADH | 65–96%8,18,21 | 43–70%8,18 |
Panhypopituitarism*** | 43–100%8,18,64 | 59–74%8,18,64 |
Obesity** | 44–64%8,9,19,64 | 41–47%8,19,64 |